

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and treating... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1348/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1348" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and treating immunoglobulin light chain amyloidosis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and treating immunoglobulin light chain amyloidosis.">
            <meta name="og:description" content="Read the latest article version by Talha Badar, Anita D'Souza, Parameswaran Hari, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16729">
            <meta name="article-id" content="15353">
            <meta name="dc.title" content="Recent advances in understanding and treating immunoglobulin light chain amyloidosis">
            <meta name="dc.description" content="Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses.">
            <meta name="dc.subject" content="AL amyloidosis, cardiac amyloidosis, dFLC, autologous transplant for AL amyloidosis">
            <meta name="dc.creator" content="Badar, Talha">
            <meta name="dc.creator" content="D'Souza, Anita">
            <meta name="dc.creator" content="Hari, Parameswaran">
            <meta name="dc.date" content="2018/08/29">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15353.1">
            <meta name="dc.source" content="F1000Research 2018 7:1348">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="AL amyloidosis">
            <meta name="prism.keyword" content="cardiac amyloidosis">
            <meta name="prism.keyword" content="dFLC">
            <meta name="prism.keyword" content="autologous transplant for AL amyloidosis">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/29">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1348">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15353.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1348">
            <meta name="citation_title" content="Recent advances in understanding and treating immunoglobulin light chain amyloidosis">
            <meta name="citation_abstract" content="Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses.">
            <meta name="citation_description" content="Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses.">
            <meta name="citation_keywords" content="AL amyloidosis, cardiac amyloidosis, dFLC, autologous transplant for AL amyloidosis">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Talha Badar">
            <meta name="citation_author_institution" content="Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA">
            <meta name="citation_author" content="Anita D'Souza">
            <meta name="citation_author_institution" content="Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA">
            <meta name="citation_author" content="Parameswaran Hari">
            <meta name="citation_author_institution" content="Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA">
            <meta name="citation_publication_date" content="2018/08/29">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1348">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15353.1">
            <meta name="citation_firstpage" content="1348">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1348/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1348.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16729 /> <input type=hidden id=articleId name=articleId value=15353 /> <input type=hidden id=xmlUrl value="/articles/7-1348/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1348-v1.xml"> <input type=hidden id=article_uuid value=9f963d18-0a36-4f6f-a5d3-b4700b1ee1ee /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and treating immunoglobulin light chain amyloidosis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15353.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15353.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1348"
  },
  "headline": "Recent advances in understanding and treating immunoglobulin light chain amyloidosis",
  "datePublished": "2018-08-29T10:07:52",
  "dateModified": "2018-08-29T10:07:52",
  "author": [
    {
      "@type": "Person",
      "name": "Talha Badar"
    },    {
      "@type": "Person",
      "name": "Anita D'Souza"
    },    {
      "@type": "Person",
      "name": "Parameswaran Hari"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1348",
            "name": "Recent advances in understanding and treating immunoglobulin light..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and treating immunoglobulin light... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16729 data-id=15353 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15353.1" data-recommended="" data-doi="10.12688/f1000research.15353.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1348/v1/pdf?article_uuid=9f963d18-0a36-4f6f-a5d3-b4700b1ee1ee" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15353-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15353-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15353-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Badar T, D'Souza A and Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1348 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15353.1" target=_blank>https://doi.org/10.12688/f1000research.15353.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15353-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15353 id=track-article-signin-15353 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15353?target=/articles/7-1348">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16729 /> <input name=articleId type=hidden value=15353 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and treating immunoglobulin light chain amyloidosis</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Talha Badar<a href="https://orcid.org/0000-0003-1548-918X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1548-918X</div>,&nbsp;</span><span class="">Anita D'Souza,&nbsp;</span><span class=""><a href="mailto:phari@mcw.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Parameswaran Hari</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Talha Badar<a href="http://orcid.org/0000-0003-1548-918X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1548-918X</div>,&nbsp;</span><span class="">Anita D'Souza,&nbsp;</span><span class=""><a href="mailto:phari@mcw.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Parameswaran Hari</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 29 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15353.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA<br/> <p> <div class=margin-bottom> Talha Badar <br/> <span>Roles: </span> Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Anita D'Souza <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Parameswaran Hari <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38297-37522></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38296-37521></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction. Owing to its diverse clinical presentations and a tendency to mimic common medical conditions, AL amyloidosis is often diagnosed late and results in dismal outcomes. Early referral to a specialized center with expertise in management of AL amyloidosis is always recommended. The availability of sensitive biomarkers and novel therapies is reforming our approach to how we manage AL amyloidosis. Treatment for patients with AL amyloidosis should be risk-adapted and customized on the basis of individual patient characteristics. In the future, approaches directed at amyloid fibril clearance in combination with agents that target plasma cells will be needed both to eradicate the malignant clone and to establish organ responses. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> AL amyloidosis, cardiac amyloidosis, dFLC, autologous transplant for AL amyloidosis </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Parameswaran Hari (<a href="mailto:phari@mcw.edu">phari@mcw.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Parameswaran Hari </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Badar T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Badar T, D'Souza A and Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1348 (<a href="https://doi.org/10.12688/f1000research.15353.1" target=_blank>https://doi.org/10.12688/f1000research.15353.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 29 Aug 2018, <b>7</b>(F1000 Faculty Rev):1348 (<a href="https://doi.org/10.12688/f1000research.15353.1" target=_blank>https://doi.org/10.12688/f1000research.15353.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 29 Aug 2018, <b>7</b>(F1000 Faculty Rev):1348 (<a href="https://doi.org/10.12688/f1000research.15353.1" target=_blank>https://doi.org/10.12688/f1000research.15353.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e164>Introduction</h2><p class="" id=d1677e167>Amyloidosis is a plasma cell disorder characterized by the extracellular deposition of pathologic, insoluble fibrillary protein in various organs of the body, leading to organ dysfunction<sup><a href="#ref-1">1</a></sup>. Amyloidosis can manifest as a localized disease or can present as systemic disease with multiple organ involvement. Localized deposits of amyloid can occur anywhere in the body and are usually light chain (LC). Common sites of localized amyloid LC (AL) amyloidosis include the orbit, pharyngeo-laryngeal region, tracheobronchial tree, pulmonary parenchyma, and urinary bladder. Localized amyloidosis has excellent prognosis, usually does not affect life expectancy, and rarely evolves to systemic disease<sup><a href="#ref-2">2</a></sup>. Systemic amyloidosis is more common than localized amyloidosis and can have serious implications. The common proteins involved in systemic amyloidosis and organ dysfunction are immunoglobulin (Ig) LCs (AL), Ig heavy chain (AH), transthyretin (ATTR), serum amyloid A (AA), apolipoprotein A-I (AApoAI), β2-microglobulin, and leukocyte chemotactic factor-2 (ALECT2)<sup><a href="#ref-3">3</a></sup>. Types of systemic amyloidosis are summarized in <a href="#T1">Table 1</a>. The most common among them in the US and Europe is AL amyloidosis, which is caused by deposition of misfolded LCs produced by a neoplastic plasma clone. In this review, we will discuss the pathophysiology, recent progress in diagnostic modalities, newer therapeutic strategies, including immunotherapy, and the role of transplant in systemic AL amyloidosis.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Types of systemic amyloidosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d1677e196 class=n-a></a><thead><a name=d1677e198 class=n-a></a><tr><a name=d1677e200 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e202 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e205 class=n-a></a>Organ involvement</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e208 class=n-a></a>Amyloid protein</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e211 class=n-a></a>Incidence</th></tr></thead><tbody><a name=d1677e216 class=n-a></a><tr><a name=d1677e218 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e220 class=n-a></a><b>AL amyloidosis (AL)</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e224 class=n-a></a>Kidney, heart, liver, GI, soft tissue,<br class=br>PNS, and ANS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e229 class=n-a></a>Ig light chain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e232 class=n-a></a>9–14 per million person-years</td></tr><tr><a name=d1677e236 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e238 class=n-a></a>AH amyloidosis (AH)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e241 class=n-a></a>Mainly kidney involvement</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e244 class=n-a></a>Ig heavy chain</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e247 class=n-a></a>Rare, incidence not reported</td></tr><tr><a name=d1677e251 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e253 class=n-a></a>Transthyretin amyloidosis<br class=br>(ATTR) </td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e258 class=n-a></a>Heart, PNS, kidney, and eye</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e261 class=n-a></a>Transthyretin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e264 class=n-a></a>70–79 years; 1.6% in AA and<br class=br>0.1% in Caucasians<br class=br>&gt;90 years; 8.2% in AA and<br class=br>2.7% in Caucasians</td></tr><tr><a name=d1677e274 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e276 class=n-a></a>Familial amyloidosis (AF)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e279 class=n-a></a>Renal, PNS, GI, and eye</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e282 class=n-a></a>Transthyretin, apolipoprotein<br class=br>AI, and cystatin C</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e287 class=n-a></a>Rare, incidence not reported</td></tr><tr><a name=d1677e291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e293 class=n-a></a>Apolipoprotein AL<br class=br>amyloidosis (AApoAI)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e298 class=n-a></a>Kidney, liver, PNS, heart, and skin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e301 class=n-a></a>Apolipoprotein AL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e304 class=n-a></a>Rare, incidence not reported</td></tr><tr><a name=d1677e309 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e311 class=n-a></a>AA amyloidosis (AA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e314 class=n-a></a>Kidney, liver, GI, ANS, and thyroid</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e317 class=n-a></a>Serum amyloid A (SAA)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e320 class=n-a></a>0.5–0.86%</td></tr><tr><a name=d1677e324 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e326 class=n-a></a>Dialysis-related amyloidosis<br class=br>(Aβ2M)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e331 class=n-a></a>Osteoarticular tissue; infrequently<br class=br>involves GI, blood vessels, and heart</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e336 class=n-a></a>β2-microglobulin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e339 class=n-a></a>21% patients on HD &lt;2 years<br class=br>50% patients on HD 4–7 years<br class=br>90% patients on HD 7–13 years</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d1677e351 class=n-a></a><p id=d1677e353> AA, African-Americans; ANS, autonomic nervous system; GI, gastrointestinal tract; HD, hemodialysis; Ig, immunoglobulin; PNS, peripheral nervous system.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e362>Pathophysiology</h2><div class=section><a name=d1677e365 class=n-a></a><h3 class=section-title>Molecular events</h3><p class="" id=d1677e370>The molecular events that take place in AL amyloidosis start with a clonal expansion of differentiated plasma cells leading to the production of amyloidogenic LCs characterized by instability and improper aggregation<sup><a href="#ref-4">4</a></sup>. These LCs and their fragments interact with extracellular matrix and glycosaminoglycans (GAGs) forming oligomers<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Serum amyloid proteins (SAPs) present in amyloid deposits prevent reabsorption of these amyloid fibrils/oligomers<sup><a href="#ref-7">7</a></sup>. Replacement of normal tissue architecture with pathologic amyloid deposits leads to organ dysfunction.</p></div><div class=section><a name=d1677e389 class=n-a></a><h3 class=section-title>Organ toxicity and tropism in amyloid</h3><p class="" id=d1677e394>The exact mechanism of amyloid deposition in various organs of the body and consequent toxicity is not completely understood. Several mechanisms of amyloid-related proteotoxicity leading to organ dysfunction have been reported in the literature. Migrino <i>et al</i>., in <i>ex vivo</i> experiments, demonstrated that AL-related myocardial dysfunction is a result of increased oxidative stress, leading to decreased nitrous oxide availability and apoptotic injury of cardiac endothelium<sup><a href="#ref-8">8</a></sup>. Colleagues from Boston University demonstrated that impaired lysosomal function is the major cause of defective autophagy and LC-induced proteotoxicity<sup><a href="#ref-9">9</a></sup>. A recent study by Marin-Argany <i>et al.</i><sup><a href="#ref-10">10</a></sup> suggested that LC fragments of amyloid are toxic even at low concentrations. They can aggregate and recruit soluble proteins, resulting in elongation of amyloid fibrils and cellular toxicity. Shi <i>et al</i>. proposed that the activation of p38 mitogen-activated protein kinase (MAPK) is one of the molecular mechanisms responsible for cardiotoxicity through an increase in cellular oxidative stress and apoptosis<sup><a href="#ref-11">11</a></sup>. This mechanism is independent of MAPK but rather dependent on transforming growth factor-beta–activated protein kinase-1 binding protein-1–dependent autophosphorylation. It is important to note that p38 MAPK signaling is the same pathway that mediates type B natriuretic peptide (BNP) transcription, supporting an association between LC cardiotoxic effects with induced MAPK signaling and elevated BNP levels. For renal amyloid, researchers have conducted <i>in vitro</i> and <i>in vivo</i> studies demonstrating that the interaction of mesangial cells with internalized LC causes the formation of amyloid fibrils, which then causes extracellular matrix proteotoxicity through lysosomes<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d1677e435>It has been hypothesized that AL amyloid manifests organ tropism which may be a function of LC variable region gene polymorphisms<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Studies have shown that LC variable region gene subtypes predispose to specific organ involvement in AL. Perfetti <i>et al</i>.<sup><a href="#ref-13">13</a></sup> conducted a study in which biopsy specimens of patients with AL amyloidosis were examined by liquid chromatography mass spectrometry. The study demonstrated that AL amyloidosis patients with LV2-14 mutation were more likely to have peripheral nerve involvement, LV1-44 mutated were more likely to have cardiac involvement and KV1-33 mutated were associated with liver involvement.</p></div><div class=section><a name=d1677e453 class=n-a></a><h3 class=section-title>Amyloidogenic clone</h3><p class="" id=d1677e458>AL amyloidosis is caused by a clonal expansion of differentiated plasma cells, which produces misfolded LCs that have the propensity to deposit in the vital organs of the body, commonly heart, kidney, liver, and nervous system<sup><a href="#ref-15">15</a></sup>. The presence of greater than 10% clonal plasma cells in the bone marrow is associated with inferior outcomes regardless of the presence or absence of myeloma like end-organ damage caused by the plasma cell clone<sup><a href="#ref-16">16</a></sup>. Next-generation sequencing data suggest that the mutational pattern of AL amyloidosis is intermediate between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. The t(11;14) and hyperdiploidy are the most commonly observed chromosomal abnormalities in amyloidogenic plasma cells; these chromosomal abnormalities are associated with the size of the plasma cell clone and relative resistance to proteosome inhibitor-based therapy<sup><a href="#ref-17">17</a></sup>. Moreover, gain of 1q21 is associated with poor response to conventional melphalan-based chemotherapy that can be overcome with proteasome inhibitor-based therapy<sup><a href="#ref-18">18</a></sup>. Hammons <i>et al</i>. conducted a retrospective review of 107 patients with AL and evaluated the prognostic impact of chromosomal abnormalities detected by fluorescent <i>in situ</i> hybridization (FISH) on diagnostic bone marrows. The study did not show any correlation between AL stage or survival at one year and chromosomal abnormalities detected by FISH, including t(4;14), 1q21, del 17p, and hypodiploidy<sup><a href="#ref-19">19</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e492>Recent advances in diagnostic modalities</h2><div class=section><a name=d1677e495 class=n-a></a><h3 class=section-title>Biomarkers</h3><p class="" id=d1677e500>Delayed diagnosis occurs in about 40% of patients with AL amyloidosis and among them 25% of patients will present with advanced cardiac disease having dismal outcome<sup><a href="#ref-20">20</a></sup>. Increased awareness about the disease and improved diagnostic modalities are needed to diagnose early and manage patients efficiently.</p><p class="" id=d1677e507>Over the last decade, the availability of biomarkers such as N-terminal pro-brain natriuretic peptide (NT-proBNP) has improved diagnostic accuracy and risk stratification<sup><a href="#ref-21">21</a></sup>. In published literature, NT-proBNP in cardiac amyloid and albuminuria in renal amyloid have shown high diagnostic accuracy<sup><a href="#ref-22">22</a></sup>. This has encouraged clinicians to adopt biomarker-based screening for AL amyloidosis in patients with monoclonal gammopathy of undetermined significance.</p><p class="" id=d1677e518>Moreover, quantification and monitoring of Ig free LC (FLC) assay have been validated for diagnosis and risk stratification and to assess response to treatment<sup><a href="#ref-23">23</a></sup>. Lately, sensitive mass spectrometry–based technologies have been developed for monoclonal FLC detection and quantification, which have improved test sensitivity<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d1677e529>Timing of treatment during relapse in AL has been controversial because of the time delay between hematological and subsequent organ progression. Palladini <i>et al</i>. recently evaluated clinical outcome of patients with relapsed AL amyloidosis who had initially responded to non-transplant therapies<sup><a href="#ref-25">25</a></sup>. They identified patients with probability for high risk of progression on the basis of difference between involved and uninvolved FLC (dFLC). Patients with a dFLC of more than 20 mg/dL or a 20% increase in dFLC from baseline at relapse or more than 50% increase in dFLC from nadir were defined as “high-risk dFLC progression” and these patients had inferior outcomes despite relatively small increases in FLC<sup><a href="#ref-25">25</a></sup>. The study suggests that patients with high-risk dFLC receive salvage therapies earlier before clinical evidence of organ progression.</p></div><div class=section><a name=d1677e544 class=n-a></a><h3 class=section-title>Imaging</h3><p class="" id=d1677e549>For several decades, echocardiography has been the diagnostic imaging modality of choice for detecting cardiac amyloid. Recently, advanced cardiac magnetic resonance imaging using T1 mapping and extracellular volume measurements has been adopted for diagnosis of cardiac amyloid with good specificity and capability to provide desired anatomical details and prognostic information<sup><a href="#ref-26">26</a></sup>. Additionally, recognizing distinct myocardial strain patterns and its association with cardiac amyloidosis has further enhanced the utility of cardiac imaging in amyloid<sup><a href="#ref-27">27</a></sup>. Tracers used for imaging β-amyloid protein in the brain for Alzheimer’s disease—<sup>11</sup>C-labeled Pittsburgh compound B (<sup>11</sup>C-PIB), <sup>18</sup>F-florbetapir, and <sup>18</sup>F-florbetaben—have very high sensitivity for amyloid and have been used for imaging cardiac AL amyloidosis<sup><a href="#ref-4">4</a>,<a href="#ref-28">28</a></sup>. The bone-seeking radionucleotide tracers <sup>99m</sup>Tc-3,3-diphosphono-1,2 propanodicarboxylic acid, <sup>99m</sup>Tc-hydroxymethylene diphosphonate, and <sup>99m</sup>Tc-pyrophosphate have shown high sensitivity for cardiac ATTR deposits and can be used to differentiate AL amyloidosis<sup><a href="#ref-29">29</a></sup>.</p><p class="" id=d1677e593>Few novel strategies have been proposed in the past to efficiently diagnose systemic amyloidosis but none of them has been implemented in clinics yet. Hawkins <i>et al</i>. proposed radionuclide imaging using serum amyloid P (SAP) with the capability of evaluating the kinetics of amyloid deposition and regression of amyloid precursors after therapy<sup><a href="#ref-30">30</a></sup>. One drawback of this test is that it cannot detect cardiac amyloid. Another innovative strategy is to use serine protease inhibitor (aprotinin) labeled with technetium 99 (<sup>99m</sup>Tc) that potentially detects early amyloid deposition in vital organs of the body<sup><a href="#ref-28">28</a></sup>. These tests require further study and validation before being implemented in clinical practice.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e614>Amyloid typing</h2><p class="" id=d1677e617>Once amyloid is identified, typing should be carried out for further characterization. Historically, immunohistochemistry was used for amyloid typing but the test has low sensitivity and specificity. Since then, electron and immuno-electron microscopy has been shown to correctly identify and characterize patients with amyloidosis<sup><a href="#ref-31">31</a></sup>. Similarly, direct immunofluorescence microscopy is another method for amyloid typing, commonly performed on kidney biopsies. Immunofluorescence using fluorescein isothiocyanate (FITC)-labeled antibodies to IgA, IgM, IgG, κ, and λ LC are used for amyloid typing. Vrana <i>et al</i>. reported a more sensitive method of amyloid typing by combining laser microdissection and mass spectrometry–based proteomic analysis<sup><a href="#ref-32">32</a></sup>. The test was validated in 41 cardiac amyloid patients with 100% sensitivity and specificity. Once the Ig component involved in amyloidogenesis is identified, further therapy can be implemented.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e634>Clinical presentation</h2><p class="" id=d1677e637>Clinical presentation is variable depending on the organ involved. AL amyloidosis can involve any organ in the body except the brain:heart (82%), kidney (68%), soft tissue (17%), liver (14%), peripheral/autonomic nervous system (12%), and gastrointestinal tract (8%)<sup><a href="#ref-4">4</a></sup>. Among them, cardiac involvement is the main determinant of early mortality<sup><a href="#ref-33">33</a></sup>. Early diagnosis is vitally important before the development of advance cardiomyopathy to improve outcomes. There are certain “red flag” signs of AL that all physicians should be aware of in order to make a prompt diagnosis; these include soft tissue amyloid infiltrates (that is, macroglossia and bilateral carpal tunnel syndrome), nephrotic syndrome, autonomic dysfunction (that is, orthostatic hypotension, nocturnal diarrhea, and erectile dysfunction), bleeding (that is, cutaneous and periorbital ecchymosis), and genetic predisposition (that is, family and ethnicity).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e652>Treatment</h2><p class="" id=d1677e655>The outcome of AL amyloidosis with advanced disease has improved in the most recent decade with the incorporation of novel drugs such as proteasome inhibitors and consolidation therapy with autologous hematopoietic cell transplant (autoHCT). A recent report of 1,551 patients with AL amyloidosis revealed that about one third of the patients are achieving a median survival of more than 10 years<sup><a href="#ref-34">34</a></sup>. In recent years, early mortality appears to have improved from 40% at 6 months<sup><a href="#ref-35">35</a></sup> to 24% at 6 months<sup><a href="#ref-34">34</a></sup>.</p><div class=section><a name=d1677e670 class=n-a></a><h3 class=section-title>Novel therapies</h3><p class="" id=d1677e675>Before the advent of novel therapies, limited options existed for patients with AL amyloidosis. For several years, melphalan-dexamethasone (MDex) was the standard-of-care upfront treatment for AL amyloidosis<sup><a href="#ref-36">36</a></sup>. The introduction of bortezomib has been a revolution in producing rapid hematologic responses in patients with AL amyloidosis. In a matched control study of AL amyloidosis, complete response (CR) was observed in 42% of patients who received a bortezomib, melphalan, and dexamethasone (BMDex) combination compared with 19% with MDex alone<sup><a href="#ref-37">37</a></sup>. In another study, data of 230 patients with AL amyloidosis were retrospectively evaluated for response to an upfront cyclophosphamide, bortezomib, and dexamethasone (CyBorD) combination regimen. The overall hematological response rate observed was 60%; among them, 23% achieved CR<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d1677e690>A lenalidomide, melphalan, and dexamethasone (LMDex) combination has been tested in transplant-ineligible, treatment-naïve patients and demonstrated response rates of 50% (n = 25/50) compared with 24% (n = 12/49) in historical matched patients who received MDex only. Higher response rates with LMDex regimen were translated into improved event-free survival and overall survival (OS)<sup><a href="#ref-39">39</a></sup>. Similarly, an upfront lenalidomide, cyclophosphamide, and dexamethasone combination was evaluated in a single-arm, phase II study in patients with AL amyloidosis<sup><a href="#ref-40">40</a></sup>. The overall response rate (ORR) was 60%, but none of the patients achieved CR. Hematological toxicity was the major adverse event noted.</p><p class="" id=d1677e701>Immunomodulatory agents (IMiDs), including thalidomide<sup><a href="#ref-41">41</a></sup>, lenalidomide<sup><a href="#ref-42">42</a></sup>, and pomalidomide<sup><a href="#ref-43">43</a></sup>, have shown significant activity in patients with relapsed refractory AL amyloidosis with the hypothesis that these drugs can overcome the resistance to alkylating agent therapy. In the relapsed refractory population, treatment with IMiDs demonstrated ORR in the range of 50 to 70%, although a smaller proportion of patients achieved CR<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. However, IMiD-based regimens should be used with caution in patients with proteinuria. Moreover, these drugs can be associated with significant hematologic toxicities, fluid retention, and increase in cardiac biomarkers in AL amyloidosis and hence these patients warrant active surveillance while on therapy. <a href="#T2">Table 2</a> summarizes salvage chemotherapy regimens in patients with relapsed refractory AL amyloidosis.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Outcome of relapsed refractory amyloid light-chain amyloidosis with salvage treatment regimens.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d1677e737 class=n-a></a><thead><a name=d1677e739 class=n-a></a><tr><a name=d1677e741 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e743 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e746 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e749 class=n-a></a>Patients, number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e752 class=n-a></a>Hematological<br class=br>response<br class=br>percentage (CR<br class=br>percentage)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e761 class=n-a></a>Organ<br class=br>response</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e767 class=n-a></a>Progression-<br class=br>free survival</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e772 class=n-a></a>Overall<br class=br>survival</th></tr></thead><tbody><a name=d1677e779 class=n-a></a><tr><a name=d1677e781 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e783 class=n-a></a>Phase III<sup><a href="#ref-48">48</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e789 class=n-a></a>HDM → autoHCT<br class=br>versus MDex</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e794 class=n-a></a>100 (50<br class=br>in each<br class=br>group)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e801 class=n-a></a>72 versus 74</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e804 class=n-a></a>45%<br class=br>versus<br class=br>39%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e812 class=n-a></a>32 versus<br class=br>32.5 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e817 class=n-a></a>22.2 versus<br class=br>56.9 months</td></tr><tr><a name=d1677e823 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e825 class=n-a></a>Retrospective<sup><a href="#ref-49">49</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e831 class=n-a></a>Bendamustine +<br class=br>prednisone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e836 class=n-a></a>36</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e839 class=n-a></a>47 (3)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e842 class=n-a></a>12%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e846 class=n-a></a>NR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e849 class=n-a></a>65% alive at<br class=br>3 years</td></tr><tr><a name=d1677e855 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e857 class=n-a></a>Phase II<sup><a href="#ref-43">43</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e863 class=n-a></a>Pomalidomide and<br class=br>dexamethasone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e868 class=n-a></a>28</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e871 class=n-a></a>68 (29)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e874 class=n-a></a>Renal<br class=br>response<br class=br>2/12 (17%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e882 class=n-a></a>16 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e885 class=n-a></a>26 months</td></tr><tr><a name=d1677e889 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e891 class=n-a></a>Phase I/II<sup><a href="#ref-50">50</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e897 class=n-a></a>Ixazomib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e900 class=n-a></a>27</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e903 class=n-a></a>52(4)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e906 class=n-a></a>56% (renal<br class=br>45%,<br class=br>cardiac<br class=br>45%)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e916 class=n-a></a>15 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e919 class=n-a></a>86% at 1 year</td></tr><tr><a name=d1677e923 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e925 class=n-a></a>Phase I<sup><a href="#ref-51">51</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e931 class=n-a></a>Carfilzomib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e934 class=n-a></a>24</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e937 class=n-a></a>63 (13)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e940 class=n-a></a>21%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e944 class=n-a></a>20 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e947 class=n-a></a>NR</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d1677e955 class=n-a></a><p id=d1677e957> autoHCT, autologous hematopoietic cell transplant; CR, complete response; HDM, high-dose melphalan; MDex, melphalan + dexamethasone; NR, not reached.</p></div></div></div></div><div class=section><a name=d1677e964 class=n-a></a><h3 class=section-title>Immunotherapy</h3><p class="" id=d1677e969>Daratumumab is a human IgG1κ monoclonal antibody that targets CD38 surface antigen on plasma cells and is now an important component of multiple myeloma therapy. Daratumumab has recently been evaluated in patients with AL amyloidosis. In one retrospective analysis of 25 relapsed refractory patients, it showed a remarkable ORR of 76% and a CR rate of 36%<sup><a href="#ref-44">44</a></sup>. Consequently, several prospective trials are evaluating efficacy of daratumumab in AL amyloidosis, including a phase 3, CyBorD plus daratumumab versus CyBorD alone as upfront therapy (ClinicalTrials.gov Identifier NCT03201965), daratumumab as a single agent in relapsed refractory AL amyloidosis (ClinicalTrials.gov Identifier NCT02816476), and daratumumab, ixazomib, and dexamethasone in previously treated AL amyloidosis (ClinicalTrials.gov Identifier NCT03283917).</p></div><div class=section><a name=d1677e977 class=n-a></a><h3 class=section-title>Fibril-directed therapies</h3><p class="" id=d1677e982>Doxycycline is a bacteriostatic antibiotic that binds to 30S and 50S ribosomal subunits, inhibiting protein synthesis. It has been shown to interfere with amyloid fibril formation in pre-clinical studies<sup><a href="#ref-45">45</a></sup>. Subsequently, in a retrospective analysis of 30 cardiac amyloid patients and comparison with matched controls, the addition of doxycycline to standard chemotherapy suggested improved survival compared with historic matched controls<sup><a href="#ref-46">46</a></sup>. Another agent discovered to have anti-fibril properties is epigallocatechin gallate (ECGC), which is one of the main polyphenols in green tea. An interesting observation was made in a retrospective analysis of 59 cardiac amyloid patients who consumed green tea regularly. Among them, 11 (19%) patients had reduction in interventricular wall thickness by at least 2 mm<sup><a href="#ref-47">47</a></sup>. Prospective studies are ongoing to study the efficacy of ECGC in patients with cardiac amyloid (ClinicalTrials.gov Identifier NCT02015312). <a href="#T3">Table 3</a> summarizes innovative approaches in the management of patients with AL amyloidosis.</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Novel therapies for light-chain amyloidosis.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d1677e1011 class=n-a></a><thead><a name=d1677e1013 class=n-a></a><tr><a name=d1677e1015 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e1017 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e1020 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e1023 class=n-a></a>Patients,<br class=br>number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e1028 class=n-a></a>Response</th><th align=left colspan=1 rowspan=1 valign=top><a name=d1677e1031 class=n-a></a>Adverse events</th></tr></thead><tbody><a name=d1677e1036 class=n-a></a><tr><a name=d1677e1038 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1040 class=n-a></a>Retrospective<sup><a href="#ref-44">44</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1046 class=n-a></a>Daratumumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1049 class=n-a></a>25</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1052 class=n-a></a>HR: ORR 76%, CR 36%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1055 class=n-a></a>Infusion reaction GI-II </td></tr><tr><a name=d1677e1059 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1061 class=n-a></a>Retrospective<sup><a href="#ref-60">60</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1067 class=n-a></a>Doxycycline<sup><a href="#TFN1">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1073 class=n-a></a>30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1076 class=n-a></a>HR 56% versus 33%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1079 class=n-a></a>Photosensitive rash 3 </td></tr><tr><a name=d1677e1083 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1085 class=n-a></a>Phase I/II<sup><a href="#ref-52">52</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1091 class=n-a></a>NEOD001<sup><a href="#TFN1">b</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1097 class=n-a></a>27</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1100 class=n-a></a>Cardiac 43%, renal 60%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1103 class=n-a></a>None</td></tr><tr><a name=d1677e1107 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1109 class=n-a></a>Case control<sup><a href="#ref-47">47</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1115 class=n-a></a>Epigallocatechin-3-gallate<sup><a href="#TFN1">c</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1121 class=n-a></a>59</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1124 class=n-a></a>Cardiac 19%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1127 class=n-a></a>None</td></tr><tr><a name=d1677e1131 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1133 class=n-a></a>Phase I/Ib<sup><a href="#ref-61">61</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1139 class=n-a></a>CAEL-101</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1142 class=n-a></a>24</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1145 class=n-a></a>Cardiac 67%, renal 50%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d1677e1148 class=n-a></a>Diarrhea and rash GI-II</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d1677e1156 class=n-a></a><p id=TFN1> <sup>a</sup>Given adjuvant to chemotherapy compared with matched control. <sup>b</sup>Monoclonal antibody targeting misfolded protein. <sup>c</sup>Given in addition to standard therapy. CR, complete response; G, grade; HR, hematological response; ORR, overall response rate.</p></div></div></div><p class="" id=d1677e1172>A novel approach is to use monoclonal antibody to target amyloid fibrils. The monoclonal antibody, NEOD001, directed against an LC cryptic epitope on amyloid fibrils was developed and evaluated in a phase I/II study<sup><a href="#ref-52">52</a></sup>. Among the 27 patients who had more than partial response with previous therapy, NEOD001 showed cardiac and renal response rates of 57% and 60%, respectively. Subsequently, phase IIb and III studies of NEOD001 were conducted but found to be ineffective. The drug has since been discontinued in AL<sup><a href="#ref-53">53</a></sup>.</p><p class="" id=d1677e1183>A second novel chimeric fibril-reactive monoclonal antibody, II-IF4 (CAEL-101), has also been evaluated in a phase 1/1b study in patients with relapsed refractory AL amyloidosis. The study demonstrated overall organ response of 63% (14/24), 67% (8/12) cardiac response, and 50% (5/10) renal response<sup><a href="#ref-54">54</a></sup>. The median times to response were 21 and 28 days in cardiac and renal amyloid, respectively. For further evaluation of the effectiveness of CAEL-101, phase IIb/III studies are planned to be conducted soon. Other fibril-directed strategies for amyloidosis include dezamizumab, an anti-SAP antibody, combined with miridesap; a small-molecule CPHPC which depletes circulating SAP, showed activity in a phase I clinical trial in effectively removing amyloid deposits from liver, kidney, and other organs<sup><a href="#ref-55">55</a></sup>. A phase II study evaluating the efficacy of anti-SAP monoclonal antibody in cardiac amyloid is ongoing in Europe and the US (ClinicalTrials.gov Identifier NCT03044353).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e1198>Autologous hematopoietic cell transplant</h2><p class="" id=d1677e1201>Compared with multiple myeloma, autoHCT in AL is associated with higher morbidity and mortality. A randomized phase III trial comparing autoHCT with oral melphalan/dexamethasone in AL amyloidosis was completed in 2007<sup><a href="#ref-48">48</a></sup>. The study did not show a survival benefit with autoHCT and was associated with high transplant-related mortality (TRM) of around 24%. Lack of benefit from autoHCT may be due to the fact that 13 out of 50 patients randomly assigned to the autoHCT arm did not receive transplant and one third of the transplanted patients received a lower dose of melphalan for conditioning. Subsequently, a large database analysis of over 1,500 AL amyloidosis patients who underwent autoHCT between 1995 and 2012 in the US and Canada showed significantly decreased day 100 post-transplant mortality from 20% (1995–2000) to 5% (2007–2012)<sup><a href="#ref-56">56</a></sup>. Estimated five-year OS had also improved from 55% (1995–2000) to 77% (2007–2012). Furthermore, transplants carried out at centers conducting more than at least four transplants per year had lower TRM. Factors associated with survival included performance score, absence of cardiac amyloid, or renal failure. Thus, among carefully selected patients, autoHCT can be used with good effect and can improve long-term outcomes. Recently, reports suggest that risk-adaptive dosing of melphalan and consolidation therapy post-transplant with novel agents such as bortezomib can decrease TRM and improve response rates in patients with AL amyloidosis<sup><a href="#ref-57">57</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e1219>Supportive care in amyloid light-chain amyloidosis</h2><p class="" id=d1677e1222>Since AL amyloidosis can involve multiple organs and have a wide spectrum of clinical manifestations, good supportive care is equally important, especially during the peri-transplant and active chemotherapy phases as these treatments have inherent organ toxicities<sup><a href="#ref-48">48</a>,<a href="#ref-58">58</a></sup>. Fluid management should be dealt with cautiously as there is a risk of cardio-renal syndrome even with mild intravascular volume depletion. Studies have shown that AL amyloidosis is more prone to bleeding due to related bleeding diathesis and can have an acquired factor X deficiency; hence prophylactic anti-coagulation should be used with caution<sup><a href="#ref-59">59</a></sup>. Severe autonomic neuropathy associated with AL amyloidosis can lead to debilitating orthostatic hypotension but may be managed with alpha-1 adrenergic agonists such midodrine and other measures such as anti-gravity stockings. Patients with severe malnutrition from gastrointestinal amyloidosis may need parenteral nutrition. Thus, the management of patients with AL amyloidosis warrants a multi-disciplinary team approach with immense care toward supportive measures in addition to chemotherapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1677e1239>Conclusions and future directions</h2><p class="" id=d1677e1242>The outcome of AL amyloidosis has improved over the last decade with more sensitive diagnostic modalities, incorporation of novel therapies, improved risk stratification for therapies, and improved supportive care. But there are still several areas of improvement for this rare and orphan disease. Significant proportions of patients are diagnosed too late, and delayed diagnosis remains a critical unmet need for patients. Increased awareness among all clinicians regarding the diverse yet unique clinical presentation of AL amyloidosis is of key importance. Incorporation of more sensitive biomarkers with novel imaging methods specific to amyloid, such as amyloid-sensitive nuclear imaging, can help in early diagnosis and more efficient management. Utilization of immunotherapy as a bridge to transplant in patients ineligible for high-dose chemotherapy can help in decreasing amyloid clone and improving patient eligibility for transplant. Newer fibril-directed therapies may further improve early mortality of patients in the first 6 to 12 months after diagnosis. In the future, the development of therapies targeting stabilization of the LC variable region, counteracting proteotoxicity caused by misfolded Ig LC, has the potential to improve outcomes of patients with AL amyloidosis.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d1677e1 class=n-a></a><h2 class=main-title id=d1891>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d1677e1249 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d2089>References</h2><div class="section ref-list"><a name=d1677e1249 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d1677e1256 class=n-a></a>Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses. <i>N Engl J Med.</i> 1997; <b>337</b>(13): 898–909. <a target=xrefwindow id=d1677e1264 href="http://www.ncbi.nlm.nih.gov/pubmed/9302305">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1267 href="http://dx.doi.org/10.1056/NEJM199709253371306">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d1677e1276 class=n-a></a>Mahmood S, Bridoux F, Venner CP, <i> et al.</i>: Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. <i>Lancet Haematol.</i> 2015; <b>2</b>(6): e241–50. <a target=xrefwindow id=d1677e1287 href="http://www.ncbi.nlm.nih.gov/pubmed/26688234">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1290 href="http://dx.doi.org/10.1016/S2352-3026(15)00068-X">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727056344"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1299 class=n-a></a>Sipe JD, Benson MD, Buxbaum JN, <i> et al.</i>: Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. <i>Amyloid.</i> 2016; <b>23</b>(4): 209–13. <a target=xrefwindow id=d1677e1310 href="http://www.ncbi.nlm.nih.gov/pubmed/27884064">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1313 href="http://dx.doi.org/10.1080/13506129.2016.1257986">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727056344">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733668127"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1326 class=n-a></a>Merlini G: AL amyloidosis: from molecular mechanisms to targeted therapies. <i>Hematology Am Soc Hematol Educ Program.</i> 2017; <b>2017</b>(1): 1–12. <a target=xrefwindow id=d1677e1334 href="http://www.ncbi.nlm.nih.gov/pubmed/29222231">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1337 href="http://dx.doi.org/10.1182/asheducation-2017.1.1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733668127">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727607184"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1350 class=n-a></a>Chiti F, Dobson CM: Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. <i>Annu Rev Biochem.</i> 2017; <b>86</b>: 27–68. <a target=xrefwindow id=d1677e1358 href="http://www.ncbi.nlm.nih.gov/pubmed/28498720">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1361 href="http://dx.doi.org/10.1146/annurev-biochem-061516-045115">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727607184">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d1677e1375 class=n-a></a>Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. <i>N Engl J Med.</i> 2003; <b>349</b>(6): 583–96. <a target=xrefwindow id=d1677e1383 href="http://www.ncbi.nlm.nih.gov/pubmed/12904524">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1386 href="http://dx.doi.org/10.1056/NEJMra023144">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726694515"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1395 class=n-a></a>Morgan GJ, Kelly JW: The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. <i>J Mol Biol.</i> 2016; <b>428</b>(21): 4280–97. <a target=xrefwindow id=d1677e1403 href="http://www.ncbi.nlm.nih.gov/pubmed/27569045">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1406 href="http://dx.doi.org/10.1016/j.jmb.2016.08.021">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5065776">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726694515">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d1677e1422 class=n-a></a>Migrino RQ, Truran S, Gutterman DD, <i> et al.</i>: Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. <i>Am J Physiol Heart Circ Physiol.</i> 2011; <b>301</b>(6): H2305–12. <a target=xrefwindow id=d1677e1433 href="http://www.ncbi.nlm.nih.gov/pubmed/21963839">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1436 href="http://dx.doi.org/10.1152/ajpheart.00503.2011">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1440 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3233808">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d1677e1449 class=n-a></a>Guan J, Mishra S, Qiu Y, <i> et al.</i>: Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. <i>EMBO Mol Med.</i> 2014; <b>6</b>(11): 1493–507. <a target=xrefwindow id=d1677e1460 href="http://www.ncbi.nlm.nih.gov/pubmed/25319546">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1463 href="http://dx.doi.org/10.15252/emmm.201404190">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4237473">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726578529"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1476 class=n-a></a>Marin-Argany M, Lin Y, Misra P, <i> et al.</i>: Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING. <i>J Biol Chem.</i> 2016; <b>291</b>(38): 19813–25. <a target=xrefwindow id=d1677e1487 href="http://www.ncbi.nlm.nih.gov/pubmed/27462073">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1490 href="http://dx.doi.org/10.1074/jbc.M116.736736">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1494 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5025671">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726578529">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d1677e1507 class=n-a></a>Shi J, Guan J, Jiang B, <i> et al.</i>: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(9): 4188–93. <a target=xrefwindow id=d1677e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/20150510">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1521 href="http://dx.doi.org/10.1073/pnas.0912263107">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2840082">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d1677e1535 class=n-a></a>Teng J, Turbat-Herrera EA, Herrera GA: Extrusion of amyloid fibrils to the extracellular space in experimental mesangial AL-amyloidosis: transmission and scanning electron microscopy studies and correlation with renal biopsy observations. <i>Ultrastruct Pathol.</i> 2014; <b>38</b>(2): 104–15. <a target=xrefwindow id=d1677e1543 href="http://www.ncbi.nlm.nih.gov/pubmed/24460740">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1546 href="http://dx.doi.org/10.3109/01913123.2013.861568">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d1677e1555 class=n-a></a>Perfetti V, Palladini G, Casarini S, <i> et al.</i>: The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, <i>IGLV1-44</i>. <i>Blood.</i> 2012; <b>119</b>(1): 144–50. <a target=xrefwindow id=d1677e1569 href="http://www.ncbi.nlm.nih.gov/pubmed/22067386">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1573 href="http://dx.doi.org/10.1182/blood-2011-05-355784">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726994694"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1582 class=n-a></a>Kourelis TV, Dasari S, Theis JD, <i> et al.</i>: Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. <i>Blood.</i> 2017; <b>129</b>(3): 299–306. <a target=xrefwindow id=d1677e1593 href="http://www.ncbi.nlm.nih.gov/pubmed/27856462">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1596 href="http://dx.doi.org/10.1182/blood-2016-10-743997">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726994694">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d1677e1609 class=n-a></a>Merlini G, Stone MJ: Dangerous small B-cell clones. <i>Blood.</i> 2006; <b>108</b>(8): 2520–30. <a target=xrefwindow id=d1677e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/16794250">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1620 href="http://dx.doi.org/10.1182/blood-2006-03-001164">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d1677e1629 class=n-a></a>Kourelis TV, Kumar SK, Gertz MA, <i> et al.</i>: Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. <i>J Clin Oncol.</i> 2013; <b>31</b>(34): 4319–24. <a target=xrefwindow id=d1677e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/24145344">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1643 href="http://dx.doi.org/10.1200/JCO.2013.50.8499">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881366">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d1677e1656 class=n-a></a>Bochtler T, Hegenbart U, Kunz C, <i> et al.</i>: Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. <i>J Clin Oncol.</i> 2015; <b>33</b>(12): 1371–8. <a target=xrefwindow id=d1677e1667 href="http://www.ncbi.nlm.nih.gov/pubmed/25779559">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1670 href="http://dx.doi.org/10.1200/JCO.2014.57.4947">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727248331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1680 class=n-a></a>Oliva L, Orfanelli U, Resnati M, <i> et al.</i>: The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. <i>Blood.</i> 2017; <b>129</b>(15): 2132–42. <a target=xrefwindow id=d1677e1691 href="http://www.ncbi.nlm.nih.gov/pubmed/28130214">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1694 href="http://dx.doi.org/10.1182/blood-2016-08-730978">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727248331">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d1677e1707 class=n-a></a>Hammons L, Brazauskas R, Pasquini M, <i> et al.</i>: Presence of fluorescent <i>in situ</i> hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematol Oncol Stem Cell Ther.</i> 2018; <b>11</b>(2): 105–11. <a target=xrefwindow id=d1677e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/28830801">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1725 href="http://dx.doi.org/10.1016/j.hemonc.2017.07.005">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d1677e1734 class=n-a></a>Lousada I, Comenzo RL, Landau H, <i> et al.</i>: Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. <i>Adv Ther.</i> 2015; <b>32</b>(10): 920–8. <a target=xrefwindow id=d1677e1745 href="http://www.ncbi.nlm.nih.gov/pubmed/26498944">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1748 href="http://dx.doi.org/10.1007/s12325-015-0250-0">Publisher Full Text </a> | <a target=xrefwindow id=d1677e1752 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4635176">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d1677e1761 class=n-a></a>Palladini G, Campana C, Klersy C, <i> et al.</i>: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. <i>Circulation.</i> 2003; <b>107</b>(19): 2440–5. <a target=xrefwindow id=d1677e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/12719281">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1775 href="http://dx.doi.org/10.1161/01.CIR.0000068314.02595.B2">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d1677e1784 class=n-a></a>Palladini G, Hegenbart U, Milani P, <i> et al.</i>: A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. <i>Blood.</i> 2014; <b>124</b>(15): 2325–32. <a target=xrefwindow id=d1677e1795 href="http://www.ncbi.nlm.nih.gov/pubmed/25115890">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1798 href="http://dx.doi.org/10.1182/blood-2014-04-570010">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717971155"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1807 class=n-a></a>Bradwell AR, Carr-Smith HD, Mead GP, <i> et al.</i>: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. <i>Clin Chem.</i> 2001; <b>47</b>(4): 673–80. <a target=xrefwindow id=d1677e1818 href="http://www.ncbi.nlm.nih.gov/pubmed/11274017">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717971155">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729037307"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1832 class=n-a></a>Barnidge DR, Dispenzieri A, Merlini G, <i> et al.</i>: Monitoring free light chains in serum using mass spectrometry. <i>Clin Chem Lab Med.</i> 2016; <b>54</b>(6): 1073–83. <a target=xrefwindow id=d1677e1843 href="http://www.ncbi.nlm.nih.gov/pubmed/26845720">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1846 href="http://dx.doi.org/10.1515/cclm-2015-0917">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729037307">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732073304"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1859 class=n-a></a>Palladini G, Milani P, Foli A, <i> et al.</i>: Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. <i>Blood.</i> 2018; <b>131</b>(5): 525–32. <a target=xrefwindow id=d1677e1870 href="http://www.ncbi.nlm.nih.gov/pubmed/29101236">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1873 href="http://dx.doi.org/10.1182/blood-2017-04-780544">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732073304">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d1677e1886 class=n-a></a>Fontana M, Chung R, Hawkins PN, <i> et al.</i>: Cardiovascular magnetic resonance for amyloidosis. <i>Heart Fail Rev.</i> 2015; <b>20</b>(2): 133–44. <a target=xrefwindow id=d1677e1897 href="http://www.ncbi.nlm.nih.gov/pubmed/25549885">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1900 href="http://dx.doi.org/10.1007/s10741-014-9470-7">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726849624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1909 class=n-a></a>Bhatti S, Vallurupalli S, Ambach S, <i> et al.</i>: Myocardial strain pattern in patients with cardiac amyloidosis secondary to multiple myeloma: a cardiac MRI feature tracking study. <i>Int J Cardiovasc Imaging.</i> 2018; <b>34</b>(1): 27–33. <a target=xrefwindow id=d1677e1920 href="http://www.ncbi.nlm.nih.gov/pubmed/27743139">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1923 href="http://dx.doi.org/10.1007/s10554-016-0998-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726849624">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d1677e1936 class=n-a></a>Aprile C, Marinone G, Saponaro R, <i> et al.</i>: Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. <i>Eur J Nucl Med.</i> 1995; <b>22</b>(12): 1393–401. <a target=xrefwindow id=d1677e1947 href="http://www.ncbi.nlm.nih.gov/pubmed/8586084">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1950 href="http://dx.doi.org/10.1007/BF01791147">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726330860"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e1959 class=n-a></a>Gillmore JD, Maurer MS, Falk RH, <i> et al.</i>: Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <i>Circulation.</i> 2016; <b>133</b>(24): 2404–12. <a target=xrefwindow id=d1677e1970 href="http://www.ncbi.nlm.nih.gov/pubmed/27143678">PubMed Abstract </a> | <a target=xrefwindow id=d1677e1973 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726330860">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d1677e1987 class=n-a></a>Hawkins PN, Myers MJ, Lavender JP, <i> et al.</i>: Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. <i>Lancet.</i> 1988; <b>1</b>(8600): 1413–8. <a target=xrefwindow id=d1677e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/2898580">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2001 href="http://dx.doi.org/10.1016/S0140-6736(88)92235-0">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d1677e2010 class=n-a></a>Arbustini E, Verga L, Concardi M, <i> et al.</i>: Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. <i>Amyloid.</i> 2002; <b>9</b>(2): 108–14. <a target=xrefwindow id=d1677e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/12440483">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2024 href="http://dx.doi.org/10.3109/13506120208995243">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d1677e2033 class=n-a></a>Vrana JA, Gamez JD, Madden BJ, <i> et al.</i>: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. <i>Blood.</i> 2009; <b>114</b>(24): 4957–9. <a target=xrefwindow id=d1677e2044 href="http://www.ncbi.nlm.nih.gov/pubmed/19797517">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2047 href="http://dx.doi.org/10.1182/blood-2009-07-230722">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d1677e2056 class=n-a></a>Merlini G, Palladini G: Light chain amyloidosis: the heart of the problem. <i>Haematologica.</i> 2013; <b>98</b>(10): 1492–5. <a target=xrefwindow id=d1677e2064 href="http://www.ncbi.nlm.nih.gov/pubmed/24091927">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2067 href="http://dx.doi.org/10.3324/haematol.2013.094482">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2070 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3789451">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727246779"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2079 class=n-a></a>Muchtar E, Gertz MA, Kumar SK, <i> et al.</i>: Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood.</i> 2017; <b>129</b>(15): 2111–9. <a target=xrefwindow id=d1677e2090 href="http://www.ncbi.nlm.nih.gov/pubmed/28126928">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2093 href="http://dx.doi.org/10.1182/blood-2016-11-751628">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2097 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5391625">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727246779">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d1677e2110 class=n-a></a>Kumar SK, Gertz MA, Lacy MQ, <i> et al.</i>: Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. <i>Mayo Clin Proc.</i> 2011; <b>86</b>(1): 12–8. <a target=xrefwindow id=d1677e2121 href="http://www.ncbi.nlm.nih.gov/pubmed/21193650">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2124 href="http://dx.doi.org/10.4065/mcp.2010.0480">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2128 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3012628">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d1677e2138 class=n-a></a>Palladini G, Russo P, Nuvolone M, <i> et al.</i>: Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. <i>Blood.</i> 2007; <b>110</b>(2): 787–8. <a target=xrefwindow id=d1677e2149 href="http://www.ncbi.nlm.nih.gov/pubmed/17606766">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2152 href="http://dx.doi.org/10.1182/blood-2007-02-076034">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d1677e2161 class=n-a></a>Palladini G, Milani P, Foli A, <i> et al.</i>: Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. <i>Leukemia.</i> 2014; <b>28</b>(12): 2311–6. <a target=xrefwindow id=d1677e2172 href="http://www.ncbi.nlm.nih.gov/pubmed/25059496">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2175 href="http://dx.doi.org/10.1038/leu.2014.227">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d1677e2184 class=n-a></a>Cibeira MT, Bladé J: Upfront CyBorD in AL amyloidosis. <i>Blood.</i> 2015; <b>126</b>(5): 564–6. <a target=xrefwindow id=d1677e2192 href="http://www.ncbi.nlm.nih.gov/pubmed/26228167">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2195 href="http://dx.doi.org/10.1182/blood-2015-06-648113">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727626509"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2204 class=n-a></a>Hegenbart U, Bochtler T, Benner A, <i> et al.</i>: Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. <i>Haematologica.</i> 2017; <b>102</b>(8): 1424–31. <a target=xrefwindow id=d1677e2215 href="http://www.ncbi.nlm.nih.gov/pubmed/28522573">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2218 href="http://dx.doi.org/10.3324/haematol.2016.163246">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2222 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5541875">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727626509">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d1677e2235 class=n-a></a>Kumar SK, Hayman SR, Buadi FK, <i> et al.</i>: Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood.</i> 2012; <b>119</b>(21): 4860–7. <a target=xrefwindow id=d1677e2246 href="http://www.ncbi.nlm.nih.gov/pubmed/22504925">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2249 href="http://dx.doi.org/10.1182/blood-2012-01-407791">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2253 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3418771">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d1677e2262 class=n-a></a>Wechalekar AD, Goodman HJ, Lachmann HJ, <i> et al.</i>: Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. <i>Blood.</i> 2007; <b>109</b>(2): 457–64. <a target=xrefwindow id=d1677e2273 href="http://www.ncbi.nlm.nih.gov/pubmed/16990593">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2276 href="http://dx.doi.org/10.1182/blood-2006-07-035352">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d1677e2286 class=n-a></a>Palladini G, Russo P, Foli A, <i> et al.</i>: Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. <i>Ann Hematol.</i> 2012; <b>91</b>(1): 89–92. <a target=xrefwindow id=d1677e2297 href="http://www.ncbi.nlm.nih.gov/pubmed/21533608">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2300 href="http://dx.doi.org/10.1007/s00277-011-1244-x">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727248333"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2309 class=n-a></a>Palladini G, Milani P, Foli A, <i> et al.</i>: A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. <i>Blood.</i> 2017; <b>129</b>(15): 2120–3. <a target=xrefwindow id=d1677e2320 href="http://www.ncbi.nlm.nih.gov/pubmed/28130212">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2323 href="http://dx.doi.org/10.1182/blood-2016-12-756528">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727248333">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727719962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2336 class=n-a></a>Kaufman GP, Schrier SL, Lafayette RA, <i> et al.</i>: Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. <i>Blood.</i> 2017; <b>130</b>(7): 900–2. <a target=xrefwindow id=d1677e2347 href="http://www.ncbi.nlm.nih.gov/pubmed/28615223">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2350 href="http://dx.doi.org/10.1182/blood-2017-01-763599">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727719962">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d1677e2363 class=n-a></a>Ward JE, Ren R, Toraldo G, <i> et al.</i>: Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. <i>Blood.</i> 2011; <b>118</b>(25): 6610–7. <a target=xrefwindow id=d1677e2374 href="http://www.ncbi.nlm.nih.gov/pubmed/21998211">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2377 href="http://dx.doi.org/10.1182/blood-2011-04-351643">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3242721">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727447961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2390 class=n-a></a>Wechalekar AD, Whelan C: Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. <i>Blood Cancer J.</i> 2017; <b>7</b>(3): e546. <a target=xrefwindow id=d1677e2398 href="http://www.ncbi.nlm.nih.gov/pubmed/28338670">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2401 href="http://dx.doi.org/10.1038/bcj.2017.26">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2404 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5380910">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727447961">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d1677e2417 class=n-a></a>Mereles D, Buss SJ, Hardt SE, <i> et al.</i>: Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. <i>Clin Res Cardiol.</i> 2010; <b>99</b>(8): 483–90. <a target=xrefwindow id=d1677e2428 href="http://www.ncbi.nlm.nih.gov/pubmed/20221615">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2431 href="http://dx.doi.org/10.1007/s00392-010-0142-x">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1091053"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2441 class=n-a></a>Jaccard A, Moreau P, Leblond V, <i> et al.</i>: High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. <i>N Engl J Med.</i> 2007; <b>357</b>(11): 1083–93. <a target=xrefwindow id=d1677e2452 href="http://www.ncbi.nlm.nih.gov/pubmed/17855669">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2455 href="http://dx.doi.org/10.1056/NEJMoa070484">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1091053">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d1677e2468 class=n-a></a>Palladini G, Schonland SO, Milani P, <i> et al.</i>: Treatment of AL Amyloidosis with Bendamustine. <i>Blood.</i> 2012; <b>120</b>(21): 4057. <a target=xrefwindow id=d1677e2479 href="http://www.bloodjournal.org/content/120/21/4057">Reference Source</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727658094"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2488 class=n-a></a>Sanchorawala V, Palladini G, Kukreti V, <i> et al.</i>: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood.</i> 2017; <b>130</b>(5): 597–605. <a target=xrefwindow id=d1677e2499 href="http://www.ncbi.nlm.nih.gov/pubmed/28550039">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2502 href="http://dx.doi.org/10.1182/blood-2017-03-771220">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727658094">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d1677e2515 class=n-a></a>Cohen AD, Scott EC, Liedtke M, <i> et al.</i>: A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood.</i> 2014; <b>124</b>(21): 4741. <a target=xrefwindow id=d1677e2526 href="http://www.bloodjournal.org/content/124/21/4741/tab-article-info">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726132007"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2535 class=n-a></a>Gertz MA, Landau H, Comenzo RL, <i> et al.</i>: First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. <i>J Clin Oncol.</i> 2016; <b>34</b>(10): 1097–103. <a target=xrefwindow id=d1677e2546 href="http://www.ncbi.nlm.nih.gov/pubmed/26858336">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2549 href="http://dx.doi.org/10.1200/JCO.2015.63.6530">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5470113">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726132007">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d1677e2566 class=n-a></a><a target=xrefwindow id=d1677e2567 href="http://ir.prothena.com/news-releases/news-release-details/prothena-discontinues-development-neod001-al-amyloidosis">http://ir.prothena.com/news-releases/news-release-details/prothena-discontinues-development-neod001-al-amyloidosis</a>. [updated April 23, 2018].</span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727568165"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2578 class=n-a></a>Edwards CV, Gould J, Langer AL, <i> et al.</i>: Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. <i>Amyloid.</i> 2017; <b>24</b>(sup1): 58–9. <a target=xrefwindow id=d1677e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/28434347">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2592 href="http://dx.doi.org/10.1080/13506129.2017.1292900">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727568165">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725638150"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2605 class=n-a></a>Richards DB, Cookson LM, Berges AC, <i> et al.</i>: Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. <i>N Engl J Med.</i> 2015; <b>373</b>(12): 1106–14. <a target=xrefwindow id=d1677e2616 href="http://www.ncbi.nlm.nih.gov/pubmed/26176329">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2619 href="http://dx.doi.org/10.1056/NEJMoa1504942">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725638150">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d1677e2632 class=n-a></a>D'Souza A, Dispenzieri A, Wirk B, <i> et al.</i>: Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>J Clin Oncol.</i> 2015; <b>33</b>(32): 3741–9. <a target=xrefwindow id=d1677e2643 href="http://www.ncbi.nlm.nih.gov/pubmed/26371138">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2646 href="http://dx.doi.org/10.1200/JCO.2015.62.4015">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4737858">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726673316"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1677e2659 class=n-a></a>Landau H, Smith M, Landry C, <i> et al.</i>: Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. <i>Leukemia.</i> 2017; <b>31</b>(1): 136–42. <a target=xrefwindow id=d1677e2670 href="http://www.ncbi.nlm.nih.gov/pubmed/27560108">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2673 href="http://dx.doi.org/10.1038/leu.2016.229">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2677 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5220129">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726673316">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d1677e2690 class=n-a></a>Hussain AS, Hari P, Brazauskas R, <i> et al.</i>: Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. <i>Am J Hematol.</i> 2015; <b>90</b>(11): E212–3. <a target=xrefwindow id=d1677e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/26284951">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2704 href="http://dx.doi.org/10.1002/ajh.24176">Publisher Full Text </a> | <a target=xrefwindow id=d1677e2708 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4618044">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d1677e2717 class=n-a></a>Kumar S, Dispenzieri A, Lacy MQ, <i> et al.</i>: High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. <i>Bone Marrow Transplant.</i> 2001; <b>28</b>(4): 381–5. <a target=xrefwindow id=d1677e2728 href="http://www.ncbi.nlm.nih.gov/pubmed/11571511">PubMed Abstract </a> | <a target=xrefwindow id=d1677e2731 href="http://dx.doi.org/10.1038/sj.bmt.1703155">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d1677e2741 class=n-a></a>Wechalekar A, Whelan C, Lachmann H, <i> et al.</i>: Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study. <i>Blood.</i> 2015; <b>126</b>(23): 732. <a target=xrefwindow id=d1677e2752 href="http://www.bloodjournal.org/content/126/23/732">Reference Source</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d1677e2761 class=n-a></a>Langer AL, Miao S, Mapara M, <i> et al.</i>: Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. <i>Blood.</i> 2015; <b>126</b>(23): 188. <a target=xrefwindow id=d1677e2772 href="http://www.bloodjournal.org/content/126/23/188?sso-checked=true">Reference Source</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1348&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1348&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA<br/> <p> <div class=margin-bottom> Talha Badar <br/> <span>Roles: </span> Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Anita D'Souza <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> <div class=margin-bottom> Parameswaran Hari <br/> <span>Roles: </span> Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1348/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 29 Aug 2018, 7:1348 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15353.1">https://doi.org/10.12688/f1000research.15353.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Badar T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16729 data-id=15353 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15353.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1348/v1/pdf?article_uuid=9f963d18-0a36-4f6f-a5d3-b4700b1ee1ee" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15353.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Badar T, D'Souza A and Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1348 (<a href="https://doi.org/10.12688/f1000research.15353.1" target=_blank>https://doi.org/10.12688/f1000research.15353.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15353 id=mobile-track-article-signin-15353 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15353?target=/articles/7-1348"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16729 /> <input name=articleId type=hidden value=15353 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>J Mark Sloan</strong>, Departments of Hematology/Oncology, Boston University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ahmet Dogan</strong>, Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 29 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1348&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1348&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38297-37522></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38296-37521></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1348/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>29 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>J Mark Sloan</strong>, Departments of Hematology/Oncology, Boston University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ahmet Dogan</strong>, Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1348&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1348/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and treating...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1348/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1348/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1348/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Badar T et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1348/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1348",
            templates : {
                twitter : "Recent advances in understanding and treating immunoglobulin.... Badar T et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1348/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and treating immunoglobulin light chain amyloidosis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and treating immunoglobulin light chain amyloidosis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15353/16729")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16729");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "37521": 0,
                           "37522": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "6b386cbb-8c4f-4e48-99c5-c7a0a94c5d0a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1348.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1348.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1348.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1348.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1348.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>